Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck’s Big Move: Massive Cost Cuts And R&D Changes Ahead

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck will cut 8,500 positions and reduce operating costs by $2.5 billion by 2015 to jumpstart growth in the midst of slowing sales and several late-stage pipeline setbacks. A key initiative is to recharge R&D by reinvesting in key projects and increasing business development activities.

You may also be interested in...

China Leadership Changes Signal MSD-Simcere JV Shakeup

With the two top execs at MSD-Simcere jumping ship, there was speculation that the JV could be in trouble, but MSD reiterates its strong commitment to China and the JV as the company hastens its pace in the country to introduce more products.

Despite Global Restructuring Plan, It’s Full Steam Ahead In China For Merck

Days after announcing a global restructuring plan, Merck CEO Ken Frazier visits Beijing to pledge $6 million toward the second phase of C-MAP, a public-private partnership with the Chinese government on HIV/AIDS. Frazier’s trip underscores the continuing importance of China to Merck despite a company-wide plan to cut 8,500 positions and reduce operating costs by $2.5 billion by 2015.

IL-17: Pushing The Limits Of A Drug Target

A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts